Dose-Related Safety and Immunogenicity of A Trivalent Baculovirus-Expressed Influenza-Virus Hemagglutinin Vaccine in Elderly Adults
05/2006
Journal Article
Authors:
Treanor, J.J.;
Schiff, G.M.;
Couch, R.B.;
Cate, T.R.;
Brady, R.C.;
Hay, C.M.;
Wolff, M.C.;
She, D.;
Cox, M.J.C.
Secondary:
J Infec Dis
Volume:
193
Pagination:
1223-1228
URL:
http://www.ncbi.nlm.nih.gov/pubmed/16586358
Keywords:
Antibodies-Viral; Baculoviridae; Dose-Response Relationship-Immunologic; Hemagglutinin Glycoproteins- Influenza Virus; Influenza Vaccines; Maximum Tolerated Dose; trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine; Vaccines-Inactivated
Abstract:
BACKGROUND: Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine. METHODS: In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA. RESULTS: Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 microg or 135 microg of each HA. CONCLUSIONS: Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults.
